lentiviral g1xcgd
Cell therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02234934)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cytochrome b-245 heavy chainSupplementation
CYBB supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- lentiviral g1xcgd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02234934 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | California Institute for Regenerative Medicine, Genethon, Harvard University, National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Institute for Regenerative Medicine | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Genethon | For profit | 1 | 0 | 1 | 2015 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2015 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2015 |
5 organizations
Page 1 / 1